BioPlus Acquisition Corp

BioPlus Acquisition — SPAC Merger (May 2023)

36 slides from BioPlus Acquisition's SPAC merger presentation, May 30, 2023

  1. Slide 1: Investor Presentation June 2023

    Exhibit 99.1 Investor Presentation June 2023

  2. Slide 2: Disclaimers (1 of 2)

    Disclaimers (1 of 2) This presentation and any accompanying oral presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Avertix Medical,

  3. Slide 3: Disclaimers (2 of 2)

    Disclaimers (2 of 2) Use of Data The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein

  4. Slide 4: Summary of Risk Factors (1 of 2)

    Summary of Risk Factors (1 of 2) Risks Related to Avertix’s Business • Avertix has a history of operating losses and may not achieve or sustain profitability in the future. We expect to incur losses for the foreseeable future, and our ability to achieve and maintain profitability depends on the comm

  5. Slide 5: Summary of Risk Factors (2 of 2)

    Summary of Risk Factors (2 of 2) • Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect Avertix’s business, financial condition or operations. • Avertix is subject to data privacy laws that govern the collection, use, disclosure and protect

  6. Slide 6: Avertix Executive Leadership

    Avertix Executive Leadership Tim Moran Philip Tom Peter Elia President, EVP and Chief Chief Revenue Chief Executive Officer Financial Officer Officer • Former CEO, Motus GI Holdings (Nasdaq: MOTS)• Former Principal, Explorer (Serial SPAC Sponsor)• Former Chief Strategy and Business • Former Presiden

  7. Slide 7: BIOS Board: World Class Biotech Executives with Synergistic & Complementary Skillsets

    BIOS Board: World Class Biotech Executives with Synergistic & Complementary Skillsets Ross Jonathan Ronald 1 Haghighat Rigby Eastman Chairman, CBO Vice Chairman CEO, CFO • Chairman & CEO, Triton Systems• CEO, Revolo Biotherapeutics• Senior Advisor, EW Healthcare Partners • Co-Founder, CoreTek Inc.•

  8. Slide 8: Transaction Summary Overview

    Transaction Summary 1 Overview Post-Transaction Ownership BIOS Founder & Private ▪ Fully diluted distributed pro forma enterprise value of up Placement Shares 1 to $195mm , representing 2.6x CY25E revenue Existing Avertix 11.1% Shareholders ▪ Targeting to raise $50mm in PIPE proceeds 28.5% PIPE Inve

  9. Slide 9: Before The Guardian: Fear and Anxiety of Another Heart Attack

    Before The Guardian: Fear and Anxiety of Another Heart Attack There’s reason for them to be fearful: ~8.8m What’s worse, 1 heart attack survivors in US ~25% ~1 in 5 of heart attack heart attacks survivors Every 2.6 minutes 2 will experience another are silent a heart attack survivor 2 heart attack 1

  10. Slide 10: Today: The Guardian Provides Peace of Mind & Better Decisions, Faster

    Today: The Guardian Provides Peace of Mind & Better Decisions, Faster The first and only FDA-approved implantable cardiac monitoring and 1,2 alerting platform designed for the early detection of heart attacks. • Patented and proprietary algorithm using machine learning, tailored to the individual pa

  11. Slide 11: Sizeable Global TAM with Significant Whitespace

    Sizeable Global TAM with Significant Whitespace Market Size US and Outside US (“OUS”) 1 • 8.8M existing heart attack survivors in US • Each year >800,000 heart attacks, of which >600,000 are 2 3 new , and ~90% of these patients are eligible for Guardian OUS US • The US represents a ~$7 billion addre

  12. Slide 12: We Believe Avertix Presents a De-Risked Commercial Opportunity

    We Believe Avertix Presents a De-Risked Commercial Opportunity De-Risked Foundation Compelling Commercial Opportunity • FDA Approved Class III Cardiac Device• Large Addressable Market 1 • Broad Label Indication• Robust Sales Strategy Projecting $75M Rev in ‘25 • Reimbursement Coverage• Healthy Gross

  13. Slide 13: Potential for Rapid Revenue Growth

    Potential for Rapid Revenue Growth 1 Management Projections • US sales expected to ramp to $50M in 2025 Figures in USD millions $75 • Expected nationwide sales coverage, 200+ accounts (Ambulatory Surgery Centers and Hospitals), increasing adoption & $25 productivity • Projections assume implant reve

  14. Slide 14: The Solution

    The Solution 14

  15. Slide 15: The Solution

    The Solution HARDWARE SOFTWARE Implantable Histogram REAL-TIME • Simple implantation and programming Generation ACS • Primary alerting via vibration DETECTION Intracardiac Lead Wireless Signal (1.80m) External Receiver Machine Learning • Secondary audio/visual alerting Subcutaneous IMD System uses p

  16. Slide 16: Guardian's Alerting System - Proven Benefits

    Guardian’s Alerting System - Proven Benefits Alert System “Call 911 / Emergency Alarm” Physician assesses patient’s “See Doctor” Alert non-urgent condition Guardian Proven Impact Guardian Added Benefits 4 • Speed of diagnosis 1 • Faster time to ED 4 • Speed of revascularization 2 • Asymptomatic aler

  17. Slide 17: ALERTS Clinical Study Key Findings

    ALERTS Clinical Study Key Findings: 100 Centers n=907 Impact on Time-to-Door for Heart Attacks Other Clinical Findings Symptom + alarm was 40+ 91% 26% Silent MI’s detected more predictive than Reduction in 2 2 (~20% of total) symptoms alone for unnecessary ER visits 2 real ACS event REDUCES 3 Qualit

  18. Slide 18: Commercial Strategy

    Commercial Strategy 18

  19. Slide 19: Proven Commercial Leadership Extending Reach and Talent

    Proven Commercial Leadership Extending Reach and Talent Sales Team Operational Leadership Sales Team Footprint End of 2022 Mike Gillem • Former CCO, McGinley Orthopedics, • Previously leadership roles at Foxhollow Technologies, Cayenne Medical Arin Barooah =District Sales Manager (5) • Former CRO, V

  20. Slide 20: Commercial Playbook: Network Referral & Scalable Execution Model

    Commercial Playbook: Network Referral & Scalable Execution Model Hospital and ASC Referrals Physician to Physician Referral One designated “Implanter” likely an Electrophysiologist who has expertise in Pacemakers, Implantable Cardiac Defibrillators (ICDs), etc. in the practice. Commercial Strategy •

  21. Slide 21: Our Positioning Focuses on the Unprotected Patient: EF>35

    Our Positioning Focuses on the Unprotected Patient: EF>35 “Ejection Fraction (EF) is a measurement that your physician may use to gauge how healthy your heart is. Your ejection fraction is the amount of blood that your heart pumps each time it beats.” – University of Pennsylvania Medicine EF: 35% or

  22. Slide 22: Ambulatory Surgery Centers (ASCs): A Key Focus

    Ambulatory Surgery Centers (ASCs): A Key Focus 1 2 ASC Reimbursement Dynamics % of Cardiology Procedures Performed in ASCs ASC Specific APC Payment (0525T) Total $6,266 33% Device Offset Amount -$2,903 Net APC Payment $3,659 10% Transitional Pass-Through Payment to Avertix (C1833) $10,250 4% Estimat

  23. Slide 23: Building Significant Hospital Presence & Value Analysis Approvals

    Building Significant Hospital Presence & Value Analysis Approvals 1 Hospital Reimbursement Dynamics Sample Partner Hospitals Where Guardian is Approved Hospital Specific APC Payment (0525T) Total $10,329 Device Offset Amount -$8,246 Net APC Payment $2,083 Transitional Pass-Through Payment to Avertix

  24. Slide 24: Case Studies from the Field

    1 Case Studies from the Field Early Ischemic Heart Detection with Early Arrythmia Detection Guardian ST Trending See Dr.Alert July 8th 9 December ST Deviation Trending Asymptomatic Asymptomatic patients Threshold patients diagnosed with (Max-Min >20) diagnosed Guardian Arrythmia with ST event storag

  25. Slide 25: Building a Global Business

    Building a Global Business International Strategy Partnership Activity Approval Status OUS • Avertix entered a Distribution and Supply Agreement with Hydrix in 2020 Singapore Applications Malaysia • Avertix entered a Product Distribution Agreement in MENA Approved Thailand in 2023 New Zealand • Earl

  26. Slide 26: Technology Roadmap

    Technology Roadmap 26

  27. Slide 27: The Avertix Platform

    The Avertix Platform Hardware Software Revenue Streams Implant (TPT) Physician Visits Aurora Remote Patient Monitoring Algorithm Data Capture and Monetization Expanded Adoptability MI Detection Custom Treatment Plans and Use Cases Diagnostics (Symptomatic and Silent) Compliance 27

  28. Slide 28: The Avertix Platform Expansion

    The Avertix Platform Expansion Hardware Software Revenue Streams Implant (TPT) Physician Visits Aurora Remote Patient Monitoring Algorithm Data Capture and Monetization Expanded Adoption MI Detection Custom Treatment Plans and Use Cases Diagnostics (Symptomatic and Silent) Compliance 28

  29. Slide 29: Completed and Expected Upcoming Key Milestones

    Completed and Expected Upcoming Key Milestones FY ‘23 FY ‘24 $85M MENA Agreement Aurora FDA Submission Q1 H1 Sales Force Expansion & EU MDR Submission Q1+ H1 Revenue Ramp Next GEN Aurora Design Freeze EU MDR Approval Q2 H2 Q4 MENA Regulatory Approval Next GEN Aurora FDA Approval H2 29

  30. Slide 30: Financial Profile

    Financial Profile 30

  31. Slide 31: Potential for Rapid Revenue Growth

    Potential for Rapid Revenue Growth 1 Management Projections • US sales expected to ramp to $50M in 2025 Figures in USD millions $75 • Expected nationwide sales coverage, 200+ accounts (ASCs and Hospitals), increasing adoption & productivity $25 • Projections assume implant revenue of reimbursable $1

  32. Slide 32: Avertix Revenue Streams: Significant Opportunities for Growth

    Avertix Revenue Streams: Significant Opportunities for Growth Implant Physician Patient Other Visits Subscription TPT code Remote patient Remote patient Data, reporting, monitoring: monitoring with analytics Wound check, 14 day customizable and 3, 6, 12-month notifications check-ups; alert-driven Su

  33. Slide 33: We Believe Avertix Presents a De-Risked Commercial Opportunity

    We Believe Avertix Presents a De-Risked Commercial Opportunity De-Risked Foundation Compelling Commercial Opportunity • FDA Approved Class III Cardiac Device• Large Addressable Market 1 • Broad Label Indication• Robust Sales Strategy Projecting $75M Rev in ‘25 • Reimbursement Coverage• Healthy Gross

  34. Slide 34: APPENDIX

    APPENDIX

  35. Slide 35: How We Got Here

    How We Got Here AngelMed Proprietary Aurora DEVELOPMENT 2001 - 2021 Founded Algorithm Creation Patents Guardian FDA Approval Guardian FDA Approval ALERTS Trial 6yr Implant Life 3yr Implant Life (10 Years) FDA APPROVALS Q3 2021 Q2 2018 Jan 2022 Q1 2022 Q4 2022 Q1 2023 COMMERCIALIZATION Awarded CMS 1s

  36. Slide 36: Summary Transaction Overview

    Summary Transaction Overview ◼ Avertix Medical, Inc. (“Avertix”) and BioPlus Acquisition Corp., (“BIOS”) (NASDAQ: BIOS) to combine to create a publicly listed (1) company with an up to ~$195mm enterprise value Transaction ◼ Post-closing entity expected to be listed on NASDAQ under new ticker, AVRT,

BioPlus Acquisition — SPAC Merger (May 2023) on 6ix